Current Suspected Overdose Deaths in Delaware for 2018: 259 logo

Delaware Health Alert Network #288

December 13, 2012 11:48 am

Health Alert

The Delaware Division of Public Health (DPH) is issuing this health alert to provide healthcare providers and facilities with details regarding additional contaminated medical products identified in the ongoing Food and Drug Administration (FDA) investigation associated with the fungal meningitis outbreak. In a previous DHAN, DPH reported information from the Centers for Disease Control (CDC) and FDA regarding contaminated betamethasone and cardioplegia solution. A recently released CDC Health Alert provides additional information on contaminated triamcinolone. It is unknown whether facilities in Delaware received the lots of contaminated betamethasone, triamcinolone or cardioplegia solution.


The CDC is reporting that product testing has identified bacterial contamination with several bacterial and fungal organisms in unopened vials of betamethasone, triamcinolone, and cardioplegia solution that were distributed and later recalled by NECC on October 6, 2012. To date, although CDC has received reports of illness in patients who have received the medications listed in the table below, including some patients who had evidence of meningeal inflammation, CDC and public health officials have no reports of laboratory-confirmed bacterial or fungal meningitis, spinal, or paraspinal infections caused by these products. The available epidemiological and laboratory data do not, at this time, support evidence of an outbreak of infections linked to usage of non-methylprednisolone NECC products.

The following table provides CDC and FDA laboratory testing results and product lot numbers for the contaminated triamcinolone. See the CDC health alert ( for updated information on the betamethasone and cardioplegia solution.

Medication Lot number Microbial contamination
40mg/mL injectable – 1 mL per vial
06062012@6 Bacillus lentus, Bacillus circulans
40 mg/mL injectable – 2 mL per vial
08172012@60 Aspergillus tubingensis, Penicillium sp.
40mg/mL injectable – 10 mL per vial
08242012@2 Aspergillus fumigatus


  1. Clinicians should consider these product findings when reviewing laboratory results from patients who have been exposed to a NECC product.
  2. Do not use any product produced by NECC as previously recommended by CDC and FDA.
  3. Continue follow-up of patients who received any injectable NECC product, including betamethasone, triamcinolong, and cardioplegia solution purchased from or distributed by NECC after May 21, 2012.
  4. For healthcare providers diagnosing and treating symptomatic patients who have received NECC products, CDC recommendations have not changed and can be found at

Additional Information


You are receiving this message because you are a registered member of the Delaware Health Alert Network. If you are not a member and would like to subscribe, please register at

Categories of Health Alert messages:

  • Health Alert: Conveys the highest level of importance; warrants immediate action or attention.
  • Health Advisory: Provides important information for a specific incident or situation; may not require immediate action.
  • Health Update: Provides updated information regarding an incident or situation; unlikely to require immediate action.
NOTE: This page is for informational purposes only and dated material (e.g. temporary websites) may not be available.